The CRC Digest

Curated CRC research — accessible, accurate, actionable

Monday, July 13, 2026

2 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

• ▸ GSK to Seek FDA Approval for Jemperli in Locally Advanced Rectal Cancer After Phase 2 Success

  Interim results from the phase 2 AZUR-1 study showed a "meaningful and sustained" clinical complete response rate at 12 months for Jemperli in stage 2/3 mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer, with GSK planning to submit for accelerated FDA approval. The treatment may allow some patients to avoid chemotherapy, radiation, and surgery—interventions that can lead to lifelong colostomy use, dysfunction, and infertility. (Fierce Pharma)

• ▪ Plasmonic Liquid Biopsy Platform Expanded to Early-Stage Colorectal Cancer

  Researchers have expanded a plasmonic liquid biopsy platform to early-stage colorectal cancer. (EurekAlert)

• ♥ Weighted Toxicity Score Analysis Compares Fruquintinib and Regorafenib Side Effects

  A new analysis uses weighted toxicity scores to help patients and clinicians better compare the side effect profiles of fruquintinib and regorafenib in later-line metastatic colorectal cancer treatment. (Clinical Colorectal Cancer)

• ◇ Furin Protein Sustains Tumor Signals in KRAS- and BRAF-Mutated Colorectal Cancer

  Preclinical research identifies Furin as a key mediator of the TGF-β1-COX-2 pathway in KRAS- and BRAF-mutant colorectal cancer; blocking Furin suppressed tumor growth and enhanced sensitivity to chemotherapy in organoid models. (Oncogene)

Stay informed and empowered—research moves forward every day.